Volume : 7, Issue : 5, May - 2018

INFLAMATORY BOWEL DISEASE IN CHILDREN

Dr Varun Khandagle, Dr Prakash Zacharias

Abstract :

Aims & Objectives:To study the clinical profile and effect on growth  of inflammatory bowel disease in pediatric patients in a tertiary care centre in Kerala and to explore the various treatment modalities used in pediatric inflammatory bowel disease patients. <o:p></o:p> Methodology:All patients were subjected to colonoscopy, Endoscopy and biopsies were taken from different areas. Their findings were confirmed on histopathological examinations. <o:p></o:p> Decision to perform imaging studies including USG, Barium study, CT or dynamic contrast enhanced MRI were done on a case to case basis. Final diagnosis was confirmed after combining clinical, radiological & endoscopic diagnosis &histopathological examination of endoscopic biopsy specimen. Patients were followed up periodically for surveillance. <o:p></o:p> Results: Abdominal pain was the predominant symptom in 76% of CD patients however only 50% of UC patients had abdominal pain. Though all UC patients had diarrhea, only 62.5% had blood in stool. Only 40% of CD had diarrhea as predominant symptom. Systemic symptoms including fever, anorexia were more common in CD (60%) than in UC(25%). Around 5% of Crohn’s and 62 % UC had weight loss at presentation.According to Paris classification, in our study the number of UC patients having Left sided colitis (E2) were 3(37.5%) followed by Pancolitis (E4) in 2 (25%) and Proctitis (E1) in 2 (25%) patients.<o:p></o:p> Conclusion:The peak incidence of IBD occurs in patients between the ages of 15 and 25 years.  As compared with adults, children with IBD more likely present with extensive intestinal involvement and they have rapid clinical progression .The presence of diarrhea, bloody diarrhea and urgency to defecate were found statistically significant between UC and CD groups.Both ulcerative colitis and Crohn’s disease, are chronic conditions with remissions and relapses and are associated with significant long-term morbidity<o:p></o:p>